RA Capital Management 13F holdings, Q2 2020
Holdings as of June 30, 2020 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 57 US equity positions worth $5.1bn in its Q2 2020 13F filing. The largest position was ASND at 14.2% of the reported book, followed by FORMA THERAPEUTICS HLDGS INC and NVAX. Against the Q1 2020 filing, it opened 16 new positions, added to 8 and reduced 8 among the top 50 holdings.
What did RA Capital Management own in Q2 2020? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2020 |
|---|---|---|---|---|---|---|---|
| 1 | ASND ASCENDIS PHARMA A S | Healthcare | 14.2% | $726.9m | 4,914,955 | 0% | held |
| 2 | FORMA THERAPEUTICS HLDGS INC | 8.2% | $419.0m | 9,011,651 | – | new | |
| 3 | NVAX NOVAVAX INC | Healthcare | 7.7% | $396.6m | 4,758,833 | – | new |
| 4 | CHEMOCENTRYX INC | 5.4% | $277.7m | 4,826,910 | 16% | added | |
| 5 | TGTX TG THERAPEUTICS INC | Healthcare | 4.9% | $249.1m | 12,788,457 | 23% | added |
| 6 | PCVX VAXCYTE INC | Healthcare | 3.4% | $173.5m | 5,489,181 | – | new |
| 7 | AXSM AXSOME THERAPEUTICS INC | Healthcare | 3.3% | $167.5m | 2,035,132 | 7% | added |
| 8 | ADVERUM BIOTECHNOLOGIES INC | 3.2% | $162.9m | 7,801,641 | 7% | added | |
| 9 | SATSUMA PHARMACEUTICALS INC | 2.6% | $134.7m | 4,681,858 | 0% | held | |
| 10 | ADAPY ADAPTIMMUNE THERAPEUTICS PLC | Healthcare | 2.5% | $130.7m | 13,052,464 | 4% | added |
| 11 | MGNX MACROGENICS INC | Healthcare | 2.5% | $128.0m | 4,584,652 | – | new |
| 12 | PHAT PHATHOM PHARMACEUTICALS INC | 2.5% | $125.9m | 3,825,008 | 3% | added | |
| 13 | ARVN ARVINAS INC | Healthcare | 2.4% | $123.2m | 3,672,872 | 0% | held |
| 14 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 2.3% | $116.2m | 5,210,088 | -4% | reduced |
| 15 | KALA PHARMACEUTICALS INC | 2.2% | $114.3m | 10,874,613 | 0% | held | |
| 16 | BLACK DIAMOND THERAPEUTICS INC | 2.1% | $109.2m | 2,589,904 | 0% | held | |
| 17 | LEGN LEGEND BIOTECH CORP | Healthcare | 2.1% | $105.6m | 2,481,942 | – | new |
| 18 | EIDOS THERAPEUTICS INC | 2.0% | $103.1m | 2,162,671 | 0% | held | |
| 19 | ALEC ALECTOR INC | Healthcare | 2.0% | $100.9m | 4,127,348 | 0% | held |
| 20 | ZOGENIX INC | 1.9% | $99.3m | 3,677,424 | -30% | reduced | |
| 21 | RETROPHIN INC | 1.8% | $94.6m | 4,635,687 | 11% | added | |
| 22 | MNTA MOMENTA PHARMACEUTICALS INC | 1.6% | $84.2m | 2,531,445 | 0% | held | |
| 23 | WVE WAVE LIFE SCIENCES LTD | Healthcare | 1.6% | $80.9m | 7,775,207 | 0% | held |
| 24 | IGM BIOSCIENCES INC | 1.4% | $71.7m | 982,723 | 0% | held | |
| 25 | KROS KEROS THERAPEUTICS INC | Healthcare | 1.4% | $70.3m | 1,875,000 | – | new |
| 26 | GERN GERON CORP | Healthcare | 1.3% | $65.7m | 30,126,299 | – | new |
| 27 | 89BIO INC | 1.2% | $63.0m | 3,161,214 | 0% | held | |
| 28 | AKOUOS INC | 1.0% | $51.3m | 2,281,249 | – | new | |
| 29 | TRILLIUM THERAPEUTICS INC | 1.0% | $49.9m | 6,162,694 | -3% | reduced | |
| 30 | ORCHARD THERAPEUTICS PLC | 0.9% | $45.7m | 10,403,187 | 0% | held | |
| 31 | ARDX ARDELYX INC | Healthcare | 0.8% | $43.3m | 6,260,904 | -2% | reduced |
| 32 | CRINETICS PHARMACEUTICALS INC | 0.8% | $40.8m | 2,328,698 | 19% | added | |
| 33 | RLMD RELMADA THERAPEUTICS INC | Healthcare | 0.7% | $38.1m | 851,907 | -38% | reduced |
| 34 | PREVAIL THERAPEUTICS INC | 0.7% | $37.2m | 2,494,691 | -23% | reduced | |
| 35 | ARQT ARCUTIS BIOTHERAPEUTICS INC | Healthcare | 0.7% | $35.2m | 1,165,184 | 0% | held |
| 36 | STOK STOKE THERAPEUTICS INC | Healthcare | 0.5% | $26.7m | 1,119,963 | 0% | held |
| 37 | SCPHARMACEUTICALS INC | 0.5% | $25.9m | 3,518,998 | 0% | held | |
| 38 | AVADEL PHARMACEUTICALS PLC | 0.5% | $25.3m | 3,126,131 | – | new | |
| 39 | IMARA INC | 0.4% | $22.9m | 829,348 | -43% | reduced | |
| 40 | OCUL OCULAR THERAPEUTIX INC | Healthcare | 0.4% | $22.7m | 2,727,272 | – | new |
| 41 | LRMR LARIMAR THERAPEUTICS INC | Healthcare | 0.4% | $19.5m | 1,515,151 | – | new |
| 42 | CONCERT PHARMACEUTICALS INC | 0.4% | $18.5m | 1,858,474 | 0% | held | |
| 43 | VSTM VERASTEM INC | Healthcare | 0.3% | $15.7m | 9,129,251 | -51% | reduced |
| 44 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 0.3% | $15.2m | 1,023,067 | – | new |
| 45 | CLDX CELLDEX THERAPEUTICS INC NEW | Healthcare | 0.3% | $14.9m | 1,150,000 | – | new |
| 46 | STRO SUTRO BIOPHARMA INC | Healthcare | 0.3% | $14.9m | 1,919,644 | – | new |
| 47 | SLDB SOLID BIOSCIENCES INC | 0.3% | $13.4m | 4,571,164 | 0% | held | |
| 48 | REPARE THERAPEUTICS INC | 0.2% | $12.7m | 409,000 | – | new | |
| 49 | LYRA THERAPEUTICS INC | 0.2% | $9.3m | 815,849 | – | new | |
| 50 | PASG PASSAGE BIO INC | 0.2% | $8.8m | 322,630 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.